Somatic mutations in the TP53 tumor suppressor gene occur in 25% to 33% of ACC but not in benign tumors [32], [33], suggesting that mutations in TP53 participate in tumor progression rather than in initiation. This evidence concerns the gene TP53 and adrenal cortex carcinoma.